Evidence map›Paper›PMID 34093750›Full record

ArticleExperimental and therapeutic medicine2021

Effects of

Huixiang Tian, Yueqin Li, Jie Mei, Lei Cao, Jiye Yin, Zhaoqian Liu, Juan Chen, Xiangping Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Experimental and therapeutic medicine · 2023
    Review
  5. Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Huixiang TianDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Yueqin LiDepartment of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Jie MeiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Lei CaoDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Jiye YinDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Zhaoqian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Juan ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Xiangping LiDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma is the most common subtype of non-small cell lung carcinoma. Tanshinone I is an important fat-soluble component in the extract of

Indexed as

anticancer effectdifferentially expressed geneslung adenocarcinomasalvianolatetanshinone I

Identifiers

PMID34093750
PMCPMC8170645
OpenAlexW3164785004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.